{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:29:30Z","timestamp":1792466970957,"version":"4.5.0"},"reference-count":180,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-66367-7","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T07:35:21Z","timestamp":1765524921000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Rational design of next-generation filovirus vaccines combining glycoprotein stabilization and nanoparticle display with glycan modification"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5651-863X","authenticated-orcid":false,"given":"Yi-Zong","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9053-5890","authenticated-orcid":false,"given":"Yi-Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddy L.","family":"Newby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrett","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keegan","family":"Braz Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Auclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor","family":"DesRoberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2547-968X","authenticated-orcid":false,"given":"Joel D.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7153-3769","authenticated-orcid":false,"given":"Andrew B.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn L.","family":"Stanfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linling","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1072-2694","authenticated-orcid":false,"given":"Max","family":"Crispin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6469-2419","authenticated-orcid":false,"given":"Ian A.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0259-7157","authenticated-orcid":false,"given":"Jiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"66367_CR1","unstructured":"W. Slenczka, in Marburg- and Ebolaviruses: From Ecosystems to Molecules, E. Muhlberger, L. L. Hensley, J. S. Towner, Eds., 411, pp. 3-21 (2017)."},{"key":"66367_CR2","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S0140-6736(77)92000-1","volume":"1","author":"KM Johnson","year":"1977","unstructured":"Johnson, K. M., Lange, J. V., Webb, P. A. & Murphy, F. A. Isolation and partial characterisation of a new virus causing acute haemorrhagic fever in Zaire. Lancet 1, 569\u2013571 (1977).","journal-title":"Lancet"},{"key":"66367_CR3","first-page":"571","volume":"1","author":"ET Bowen","year":"1977","unstructured":"Bowen, E. T. et al. Viral haemorrhagic fever in southern Sudan and northern Zaire. Preliminary Stud. aetiological agent. Lancet 1, 571\u2013573 (1977).","journal-title":"Preliminary Stud. aetiological agent. Lancet"},{"key":"66367_CR4","doi-asserted-by":"publisher","first-page":"20160297","DOI":"10.1098\/rstb.2016.0297","volume":"372","author":"CEM Coltart","year":"2017","unstructured":"Coltart, C. E. M., Lindsey, B., Ghinai, I., Johnson, A. M. & Heymann, D. L. The Ebola outbreak, 2013-2016: old lessons for new epidemics. Philos. Trans. R. Soc. B, Biol. Sci. 372, 20160297 (2017).","journal-title":"Philos. Trans. R. Soc. B, Biol. Sci."},{"key":"66367_CR5","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1146\/annurev-pathol-020712-164041","volume":"8","author":"S Paessler","year":"2013","unstructured":"Paessler, S. & Walker, D. H. Pathogenesis of the viral hemorrhagic fevers. Annu. Rev. Pathol. 8, 411\u2013440 (2013).","journal-title":"Annu. Rev. Pathol."},{"key":"66367_CR6","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.cll.2006.05.001","volume":"26","author":"AM Marty","year":"2006","unstructured":"Marty, A. M., Jahrling, P. B. & Gelsbert, T. W. Viral hemorrhagic fevers. Clin. Lab. Med. 26, 345\u2013386 (2006).","journal-title":"Clin. Lab. Med."},{"key":"66367_CR7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41579-019-0187-4","volume":"17","author":"JH Kuhn","year":"2019","unstructured":"Kuhn, J. H. et al. New filovirus disease classification and nomenclature. Nat. Rev. Microbiol. 17, 261\u2013263 (2019).","journal-title":"Nat. Rev. Microbiol."},{"key":"66367_CR8","first-page":"1229","volume":"159","author":"JH Kuhn","year":"2014","unstructured":"Kuhn, J. H. et al. Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA. Arch. Virol. 159, 1229\u20131237 (2014).","journal-title":"Arch. Virol."},{"key":"66367_CR9","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s00705-023-05834-2","volume":"168","author":"N Biedenkopf","year":"2023","unstructured":"Biedenkopf, N. et al. Renaming of genera Ebolavirus and Marburgvirus to Orthoebolavirus and Orthomarburgvirus, respectively, and introduction of binomial species names within family Filoviridae. Arch. Virol. 168, 220 (2023).","journal-title":"Arch. Virol."},{"key":"66367_CR10","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.virol.2015.03.043","volume":"479","author":"SC Harrison","year":"2015","unstructured":"Harrison, S. C. Viral membrane fusion. Virol 479, 498\u2013507 (2015).","journal-title":"Virol"},{"key":"66367_CR11","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1146\/annurev-virology-031413-085521","volume":"1","author":"M Kielian","year":"2014","unstructured":"Kielian, M. Mechanisms of virus membrane fusion proteins. Annu. Rev. Virol. 1, 171\u2013189 (2014).","journal-title":"Annu. Rev. Virol."},{"key":"66367_CR12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/10409230802058320","volume":"43","author":"JM White","year":"2008","unstructured":"White, J. M., Delos, S. E., Brecher, M. & Schornberg, K. Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. Crit. Rev. Biochem. Mol. Biol. 43, 189\u2013219 (2008).","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"66367_CR13","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/nsmb.1456","volume":"15","author":"SC Harrison","year":"2008","unstructured":"Harrison, S. C. Viral membrane fusion. Nat. Struct. Mol. Biol. 15, 690\u2013698 (2008).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"66367_CR14","doi-asserted-by":"publisher","first-page":"621","DOI":"10.2217\/fvl.09.56","volume":"4","author":"JE Lee","year":"2009","unstructured":"Lee, J. E. & Saphire, E. O. Ebolavirus glycoprotein structure and mechanism of entry. Future Virol. 4, 621\u2013635 (2009).","journal-title":"Future Virol."},{"key":"66367_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21411-0","volume":"12","author":"TRW Tipton","year":"2021","unstructured":"Tipton, T. R. W. et al. Characterisation of the T-cell response to Ebola virus glycoprotein amongst survivors of the 2013-16 West Africa epidemic. Nat. Commun. 12, 1153 (2021).","journal-title":"Nat. Commun."},{"key":"66367_CR16","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.cell.2015.12.022","volume":"164","author":"AI Flyak","year":"2016","unstructured":"Flyak, A. I. et al. Cross-reactive and potent neutralizing antibody responses in human survivors of natural ebolavirus infection. Cell 164, 392\u2013405 (2016).","journal-title":"Cell"},{"key":"66367_CR17","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1126\/science.aad5788","volume":"351","author":"ZA Bornholdt","year":"2016","unstructured":"Bornholdt, Z. A. et al. Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. Science 351, 1078\u20131083 (2016).","journal-title":"Science"},{"key":"66367_CR18","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3390\/pathogens11030374","volume":"11","author":"XY Yu","year":"2022","unstructured":"Yu, X. Y. & Saphire, E. O. Development and structural analysis of antibody therapeutics for filoviruses. Pathogens 11, 374 (2022).","journal-title":"Pathogens"},{"key":"66367_CR19","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.coi.2018.05.001","volume":"53","author":"LB King","year":"2018","unstructured":"King, L. B., West, B. R., Schendel, S. L. & Saphire, E. O. The structural basis for filovirus neutralization by monoclonal antibodies. Curr. Opin. Immunol. 53, 196\u2013202 (2018).","journal-title":"Curr. Opin. Immunol."},{"key":"66367_CR20","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nrd.2017.251","volume":"17","author":"RW Cross","year":"2018","unstructured":"Cross, R. W., Mire, C. E., Feldmann, H. & Geisbert, T. W. Post-exposure treatments for Ebola and Marburg virus infections. Nat. Rev. Drug Discov. 17, 413\u2013434 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"66367_CR21","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.3390\/v4091619","volume":"4","author":"BM Friedrich","year":"2012","unstructured":"Friedrich, B. M. et al. Potential vaccines and post-exposure treatments for filovirus infections. Viruses 4, 1619\u20131650 (2012).","journal-title":"Viruses"},{"key":"66367_CR22","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1093\/femsre\/fuw010","volume":"40","author":"R Burk","year":"2016","unstructured":"Burk, R. et al. Neglected filoviruses. FEMS Microbiol. Rev. 40, 494\u2013519 (2016).","journal-title":"FEMS Microbiol. Rev."},{"key":"66367_CR23","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S1473-3099(04)01103-X","volume":"4","author":"S Mahanty","year":"2004","unstructured":"Mahanty, S. & Bray, M. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect. Dis. 4, 487\u2013498 (2004).","journal-title":"Lancet Infect. Dis."},{"key":"66367_CR24","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/nrmicro3524","volume":"13","author":"I Messaoudi","year":"2015","unstructured":"Messaoudi, I., Amarasinghe, G. K. & Basler, C. F. Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus. Nat. Rev. Microbiol. 13, 663\u2013676 (2015).","journal-title":"Nat. Rev. Microbiol."},{"key":"66367_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004731","volume":"11","author":"S Moller-Tank","year":"2015","unstructured":"Moller-Tank, S. & Maury, W. Ebola virus entry: a curious and complex series of events. PLoS Pathog. 11, e1004731 (2015).","journal-title":"PLoS Pathog."},{"key":"66367_CR26","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/nature10380","volume":"477","author":"M Cote","year":"2011","unstructured":"Cote, M. et al. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 477, 344\u2013348 (2011).","journal-title":"Nature"},{"key":"66367_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44504-4","volume":"15","author":"I Khan","year":"2024","unstructured":"Khan, I. et al. Tubeimosides are pan-coronavirus and filovirus inhibitors that can block their fusion protein binding to Niemann-Pick C1. Nat. Commun. 15, 162 (2024).","journal-title":"Nat. Commun."},{"key":"66367_CR28","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.cell.2015.12.044","volume":"164","author":"H Wang","year":"2016","unstructured":"Wang, H. et al. Ebola viral glycoprotein bound to its endosomal receptor Niemann-Pick C1. Cell 164, 258\u2013268 (2016).","journal-title":"Cell"},{"key":"66367_CR29","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.coph.2016.08.016","volume":"30","author":"AP Cardile","year":"2016","unstructured":"Cardile, A. P., Downey, L. G., Wiseman, P. D., Warren, T. K. & Bavari, S. Antiviral therapeutics for the treatment of Ebola virus infection. Curr. Opin. Pharmacol. 30, 138\u2013143 (2016).","journal-title":"Curr. Opin. Pharmacol."},{"key":"66367_CR30","doi-asserted-by":"publisher","first-page":"721328","DOI":"10.3389\/fimmu.2021.721328","volume":"12","author":"OT Mbaya","year":"2021","unstructured":"Mbaya, O. T., Mukumbayi, P. & Mulangu, S. Review: insights on current FDA-approved monoclonal antibodies against Ebola virus infection. Front. Immunol. 12, 721328 (2021).","journal-title":"Front. Immunol."},{"key":"66367_CR31","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41579-019-0233-2","volume":"17","author":"T Hoenen","year":"2019","unstructured":"Hoenen, T., Groseth, A. & Feldmann, H. Therapeutic strategies to target the Ebola virus life cycle. Nat. Rev. Microbiol. 17, 593\u2013606 (2019).","journal-title":"Nat. Rev. Microbiol."},{"key":"66367_CR32","doi-asserted-by":"publisher","first-page":"e683","DOI":"10.1016\/S2666-5247(22)00123-9","volume":"3","author":"Y Gao","year":"2022","unstructured":"Gao, Y. et al. Effects of therapies for Ebola virus disease: a systematic review and network meta-analysis. Lancet Microbe 3, e683\u2013e692 (2022).","journal-title":"Lancet Microbe"},{"key":"66367_CR33","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature13777","volume":"514","author":"XG Qiu","year":"2014","unstructured":"Qiu, X. G. et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514, 47\u201353 (2014).","journal-title":"Nature"},{"key":"66367_CR34","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1056\/NEJMoa1604330","volume":"375","author":"RT Davey","year":"2016","unstructured":"Davey, R. T. et al. A randomized, controlled trial of ZMapp for Ebola virus infection. N. Engl. J. Med. 375, 1448\u20131456 (2016).","journal-title":"N. Engl. J. Med."},{"key":"66367_CR35","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40265-020-01452-3","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham, A. REGN-EB3: first approval. Drugs 81, 175\u2013178 (2021).","journal-title":"Drugs"},{"key":"66367_CR36","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1126\/science.aad5224","volume":"351","author":"D Corti","year":"2016","unstructured":"Corti, D. et al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science 351, 1339\u20131342 (2016).","journal-title":"Science"},{"key":"66367_CR37","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","volume":"381","author":"S Mulangu","year":"2019","unstructured":"Mulangu, S. et al. A randomized, controlled trial of Ebola virus disease therapeutics. N. Engl. J. Med. 381, 2293\u20132303 (2019).","journal-title":"N. Engl. J. Med."},{"key":"66367_CR38","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.tim.2016.05.008","volume":"24","author":"EO Saphire","year":"2016","unstructured":"Saphire, E. O. & Aman, M. J. Feverish quest for Ebola immunotherapy: straight or cocktail? Trends Microbiol 24, 684\u2013686 (2016).","journal-title":"Trends Microbiol"},{"key":"66367_CR39","doi-asserted-by":"publisher","first-page":"17182","DOI":"10.1073\/pnas.1414164111","volume":"111","author":"CD Murin","year":"2014","unstructured":"Murin, C. D. et al. Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proc. Natl Acad. Sci. USA 111, 17182\u201317187 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"66367_CR40","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2015.01.041","volume":"160","author":"T Hashiguchi","year":"2015","unstructured":"Hashiguchi, T. et al. Structural basis for Marburg virus neutralization by a cross-reactive human antibody. Cell 160, 904\u2013912 (2015).","journal-title":"Cell"},{"key":"66367_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005016","volume":"11","author":"ML Fusco","year":"2015","unstructured":"Fusco, M. L. et al. Protective mAbs and cross-reactive mAbs raised by immunization with engineered Marburg virus GPs. PLoS Pathog. 11, e1005016 (2015).","journal-title":"PLoS Pathog."},{"key":"66367_CR42","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.cell.2015.01.031","volume":"160","author":"AI Flyak","year":"2015","unstructured":"Flyak, A. I. et al. Mechanism of human antibody-mediated neutralization of Marburg virus. Cell 160, 893\u2013903 (2015).","journal-title":"Cell"},{"key":"66367_CR43","doi-asserted-by":"publisher","first-page":"16128","DOI":"10.1038\/nmicrobiol.2016.128","volume":"1","author":"J Pallesen","year":"2016","unstructured":"Pallesen, J. et al. Structures of Ebola virus GP and sGP in complex with therapeutic antibodies. Nat. Microbiol. 1, 16128 (2016).","journal-title":"Nat. Microbiol."},{"key":"66367_CR44","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1128\/JVI.02172-15","volume":"90","author":"ZY Keck","year":"2016","unstructured":"Keck, Z. Y. et al. Macaque monoclonal antibodies targeting novel conserved epitopes within filovirus glycoprotein. J. Virol. 90, 279\u2013291 (2016).","journal-title":"J. Virol."},{"key":"66367_CR45","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1128\/JVI.02171-15","volume":"90","author":"FW Holtsberg","year":"2016","unstructured":"Holtsberg, F. W. et al. Pan-ebolavirus and pan-filovirus mouse monoclonal antibodies: protection against Ebola and Sudan viruses. J. Virol. 90, 266\u2013278 (2016).","journal-title":"J. Virol."},{"key":"66367_CR46","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/j.celrep.2016.04.026","volume":"15","author":"KA Howell","year":"2016","unstructured":"Howell, K. A. et al. Antibody treatment of Ebola and Sudan virus infection via a uniquely exposed epitope within the glycoprotein receptor-binding site. Cell Rep. 15, 1514\u20131526 (2016).","journal-title":"Cell Rep."},{"key":"66367_CR47","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.cell.2017.04.038","volume":"169","author":"XL Zhao","year":"2017","unstructured":"Zhao, X. L. et al. Immunization-elicited broadly protective antibody reveals ebolavirus fusion loop as a site of vulnerability. Cell 169, 891\u2013904.e815 (2017).","journal-title":"Cell"},{"key":"66367_CR48","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.cell.2017.04.037","volume":"169","author":"AZ Wec","year":"2017","unstructured":"Wec, A. Z. et al. Antibodies from a human survivor define sites of vulnerability for broad protection against ebolaviruses. Cell 169, 878\u2013890.e15 (2017).","journal-title":"Cell"},{"key":"66367_CR49","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.chom.2017.12.003","volume":"23","author":"LB King","year":"2018","unstructured":"King, L. B. et al. The marburgvirus-neutralizing human monoclonal antibody MR191 targets a conserved site to block virus receptor binding. Cell Host Microbe 23, 101\u2013109.e4 (2018).","journal-title":"Cell Host Microbe"},{"key":"66367_CR50","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.immuni.2020.01.001","volume":"52","author":"P Gilchuk","year":"2020","unstructured":"Gilchuk, P. et al. Analysis of a therapeutic antibody cocktail reveals determinants for cooperative and broad ebolavirus neutralization. Immunity 52, 388\u2013403.e12 (2020).","journal-title":"Immunity"},{"key":"66367_CR51","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.immuni.2018.06.018","volume":"49","author":"P Gilchuk","year":"2018","unstructured":"Gilchuk, P. et al. Multifunctional pan-ebolavirus antibody recognizes a site of broad vulnerability on the ebolavirus glycoprotein. Immunity 49, 363\u2013374.e10 (2018).","journal-title":"Immunity"},{"key":"66367_CR52","doi-asserted-by":"publisher","first-page":"108984","DOI":"10.1016\/j.celrep.2021.108984","volume":"35","author":"CD Murin","year":"2021","unstructured":"Murin, C. D. et al. Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies. Cell Rep. 35, 108984 (2021).","journal-title":"Cell Rep."},{"key":"66367_CR53","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/s41564-018-0157-z","volume":"3","author":"AI Flyak","year":"2018","unstructured":"Flyak, A. I. et al. Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region. Nat. Microbiol. 3, 670\u2013677 (2018).","journal-title":"Nat. Microbiol."},{"key":"66367_CR54","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.celrep.2017.03.049","volume":"19","author":"KA Howell","year":"2017","unstructured":"Howell, K. A. et al. Cooperativity enables non-neutralizing antibodies to neutralize ebolavirus. Cell Rep. 19, 413\u2013424 (2017).","journal-title":"Cell Rep."},{"key":"66367_CR55","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.cell.2018.07.033","volume":"174","author":"EO Saphire","year":"2018","unstructured":"Saphire, E. O. et al. Systematic analysis of monoclonal antibodies against Ebola virus GP defines features that contribute to protection. Cell 174, 938\u2013952.e13 (2018).","journal-title":"Cell"},{"key":"66367_CR56","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nature18615","volume":"535","author":"YG Zhao","year":"2016","unstructured":"Zhao, Y. G. et al. Toremifene interacts with and destabilizes the Ebola virus glycoprotein. Nature 535, 169\u2013172 (2016).","journal-title":"Nature"},{"key":"66367_CR57","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1021\/acs.jmedchem.8b01328","volume":"62","author":"F Shaikh","year":"2019","unstructured":"Shaikh, F. et al. Structure-based in silico screening identifies a potent ebolavirus inhibitor from a traditional Chinese medicine library. J. Med. Chem. 62, 2928\u20132937 (2019).","journal-title":"J. Med. Chem."},{"key":"66367_CR58","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1021\/acs.jmedchem.7b01249","volume":"61","author":"JS Ren","year":"2018","unstructured":"Ren, J. S., Zhao, Y. G., Fry, E. E. & Stuart, D. I. Target identification and mode of action of four chemically divergent drugs against ebolavirus infection. J. Med. Chem. 61, 724\u2013733 (2018).","journal-title":"J. Med. Chem."},{"key":"66367_CR59","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/nsmb.2150","volume":"18","author":"JM Dias","year":"2011","unstructured":"Dias, J. M. et al. A shared structural solution for neutralizing ebolaviruses. Nat. Struct. Mol. Biol. 18, 1424\u20131427 (2011).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"66367_CR60","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nature07082","volume":"454","author":"JE Lee","year":"2008","unstructured":"Lee, J. E. et al. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454, 177\u2013182 (2008).","journal-title":"Nature"},{"key":"66367_CR61","doi-asserted-by":"publisher","first-page":"808047","DOI":"10.3389\/fimmu.2021.808047","volume":"12","author":"CD Murin","year":"2022","unstructured":"Murin, C. D., Gilchuk, P., Crowe, J. E. & Ward, A. B. Structural biology illuminates molecular determinants of broad ebolavirus neutralization by human antibodies for pan-ebolavirus therapeutic development. Front. Immunol. 12, 808047 (2022).","journal-title":"Front. Immunol."},{"key":"66367_CR62","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.3390\/pathogens10091201","volume":"10","author":"A Hargreaves","year":"2021","unstructured":"Hargreaves, A. et al. Filovirus neutralising antibodies: mechanisms of action and therapeutic application. Pathogens 10, 1201 (2021).","journal-title":"Pathogens"},{"key":"66367_CR63","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","volume":"389","author":"AM Henao-Restrepo","year":"2017","unstructured":"Henao-Restrepo, A. M. et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet 389, 505\u2013518 (2017).","journal-title":"Lancet"},{"key":"66367_CR64","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1001\/jama.2016.4218","volume":"315","author":"ID Milligan","year":"2016","unstructured":"Milligan, I. D. et al. Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial. J. Am. Med. Assoc. 315, 1610\u20131623 (2016).","journal-title":"J. Am. Med. Assoc."},{"key":"66367_CR65","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/infdis\/jiu511","volume":"211","author":"UN Sarwar","year":"2015","unstructured":"Sarwar, U. N. et al. Safety and immunogenicity of DNA vaccines encoding ebolavirus and marburgvirus wild-type glycoproteins in a phase I clinical trial. J. Infect. Dis. 211, 549\u2013557 (2015).","journal-title":"J. Infect. Dis."},{"key":"66367_CR66","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1056\/NEJMoa1410863","volume":"376","author":"JE Ledgerwood","year":"2017","unstructured":"Ledgerwood, J. E. et al. Chimpanzee adenovirus vector Ebola vaccine. N. Engl. J. Med. 376, 928\u2013938 (2017).","journal-title":"N. Engl. J. Med."},{"key":"66367_CR67","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","volume":"374","author":"K Ewer","year":"2016","unstructured":"Ewer, K. et al. A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA. N. Engl. J. Med. 374, 1635\u20131646 (2016).","journal-title":"N. Engl. J. Med."},{"key":"66367_CR68","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S0140-6736(16)32617-4","volume":"389","author":"FC Zhu","year":"2017","unstructured":"Zhu, F. C. et al. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 389, 621\u2013628 (2017).","journal-title":"Lancet"},{"key":"66367_CR69","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1016\/S0140-6736(15)60553-0","volume":"385","author":"FC Zhu","year":"2015","unstructured":"Zhu, F. C. et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet 385, 2272\u20132279 (2015).","journal-title":"Lancet"},{"key":"66367_CR70","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0140-6736(22)02400-X","volume":"401","author":"MJ Hamer","year":"2023","unstructured":"Hamer, M. J. et al. Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial. Lancet 401, 294\u2013302 (2023).","journal-title":"Lancet"},{"key":"66367_CR71","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S1473-3099(20)30016-5","volume":"20","author":"MD Tapia","year":"2020","unstructured":"Tapia, M. D. et al. Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial. Lancet Infect. Dis. 20, 707\u2013718 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"66367_CR72","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.vaccine.2023.12.053","volume":"42","author":"A To","year":"2024","unstructured":"To, A. et al. Thermostable bivalent filovirus vaccine protects against severe and lethal Sudan ebolavirus and marburgvirus infection. Vaccine 42, 598\u2013607 (2024).","journal-title":"Vaccine"},{"key":"66367_CR73","doi-asserted-by":"publisher","first-page":"5650","DOI":"10.1016\/j.vaccine.2021.08.003","volume":"39","author":"KB Preston","year":"2021","unstructured":"Preston, K. B. et al. Single-vial filovirus glycoprotein vaccines: biophysical characteristics and immunogenicity after co-lyophilization with adjuvant. Vaccine 39, 5650\u20135657 (2021).","journal-title":"Vaccine"},{"key":"66367_CR74","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2316960121","volume":"121","author":"D Xu","year":"2024","unstructured":"Xu, D. et al. Design of universal Ebola virus vaccine candidates via immunofocusing. Proc. Natl Acad. Sci. USA\u00a0121, e2316960121 (2024).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"66367_CR75","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1093\/infdis\/jix592","volume":"217","author":"M Meyer","year":"2018","unstructured":"Meyer, M. et al. Modified mRNA-based vaccines elicit robust immune responses and protect guinea pigs from Ebola virus disease. J. Infect. Dis. 217, 451\u2013455 (2018).","journal-title":"J. Infect. Dis."},{"key":"66367_CR76","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.3390\/vaccines11061120","volume":"11","author":"LA Parish","year":"2023","unstructured":"Parish, L. A., Stavale, E. J., Houchens, C. R. & Wolfe, D. N. Developing vaccines to improve preparedness for filovirus outbreaks: the perspective of the USA biomedical advanced research and development authority (BARDA). Vaccines 11, 1120 (2023).","journal-title":"Vaccines"},{"key":"66367_CR77","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.tim.2018.08.008","volume":"27","author":"M Meyer","year":"2019","unstructured":"Meyer, M., Malherbe, D. C. & Bukreyev, A. Can Ebola virus vaccines have universal immune correlates of protection? Trends Microbiol 27, 8\u201316 (2019).","journal-title":"Trends Microbiol"},{"key":"66367_CR78","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1038\/s41591-019-0602-4","volume":"25","author":"SA Ehrhardt","year":"2019","unstructured":"Ehrhardt, S. A. et al. Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV. Nat. Med. 25, 1589\u20131600 (2019).","journal-title":"Nat. Med."},{"key":"66367_CR79","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.chom.2020.01.007","volume":"27","author":"H Cohen-Dvashi","year":"2020","unstructured":"Cohen-Dvashi, H. et al. Structural basis for a convergent immune response against Ebola virus. Cell Host Microbe 27, 418\u2013427.e4 (2020).","journal-title":"Cell Host Microbe"},{"key":"66367_CR80","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/imr.12517","volume":"275","author":"BF Haynes","year":"2017","unstructured":"Haynes, B. F. & Mascola, J. R. The quest for an antibody-based HIV vaccine. Immunol. Rev. 275, 5\u201310 (2017).","journal-title":"Immunol. Rev."},{"key":"66367_CR81","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/nri3516","volume":"13","author":"PD Kwong","year":"2013","unstructured":"Kwong, P. D., Mascola, J. R. & Nabel, G. J. Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat. Rev. Immunol. 13, 693\u2013701 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"66367_CR82","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nbt.2197","volume":"30","author":"BF Haynes","year":"2012","unstructured":"Haynes, B. F., Kelsoe, G., Harrison, S. C. & Kepler, T. B. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat. Biotechnol. 30, 423\u2013433 (2012).","journal-title":"Nat. Biotechnol."},{"key":"66367_CR83","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.coi.2010.02.012","volume":"22","author":"LM Walker","year":"2010","unstructured":"Walker, L. M. & Burton, D. R. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr. Opin. Immunol. 22, 358\u2013366 (2010).","journal-title":"Curr. Opin. Immunol."},{"key":"66367_CR84","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1146\/annurev-med-121217-094234","volume":"70","author":"BS Graham","year":"2019","unstructured":"Graham, B. S., Gilman, M. S. A. & McLellan, J. S. Structure-based vaccine antigen design. Annu. Rev. Med. 70, 91\u2013104 (2019).","journal-title":"Annu. Rev. Med."},{"key":"66367_CR85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003618","volume":"9","author":"RW Sanders","year":"2013","unstructured":"Sanders, R. W. et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 9, e1003618 (2013).","journal-title":"PLoS Pathog."},{"key":"66367_CR86","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.celrep.2015.03.047","volume":"11","author":"SK Sharma","year":"2015","unstructured":"Sharma, S. K. et al. Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design. Cell Rep. 11, 539\u2013550 (2015).","journal-title":"Cell Rep."},{"key":"66367_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12040","volume":"7","author":"L Kong","year":"2016","unstructured":"Kong, L. et al. Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability. Nat. Commun. 7, 12040 (2016).","journal-title":"Nat. Commun."},{"key":"66367_CR88","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1126\/science.1243283","volume":"342","author":"JS McLellan","year":"2013","unstructured":"McLellan, J. S. et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342, 592\u2013598 (2013).","journal-title":"Science"},{"key":"66367_CR89","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/nsmb.3267","volume":"23","author":"MG Joyce","year":"2016","unstructured":"Joyce, M. G. et al. Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV. Nat. Struct. Mol. Biol. 23, 811\u2013820 (2016).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"66367_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9143","volume":"6","author":"A Krarup","year":"2015","unstructured":"Krarup, A. et al. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat. Commun. 6, 8143 (2015).","journal-title":"Nat. Commun."},{"key":"66367_CR91","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ade6422","volume":"15","author":"Y Che","year":"2023","unstructured":"Che, Y. et al. Rational design of a highly immunogenic prefusion- stabilized F glycoprotein antigen for a respiratory syncytial virus vaccine. Sci. Transl. Med. 15, eade6422 (2023).","journal-title":"Sci. Transl. Med."},{"key":"66367_CR92","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"66367_CR93","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","volume":"586","author":"KS Corbett","year":"2020","unstructured":"Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586, 567\u2013571 (2020).","journal-title":"Nature"},{"key":"66367_CR94","doi-asserted-by":"publisher","first-page":"101477","DOI":"10.1016\/j.eclinm.2022.101477","volume":"48","author":"KV Houser","year":"2022","unstructured":"Houser, K. V. et al. Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial. Eclinicalmedicine 48, 101477 (2022).","journal-title":"Eclinicalmedicine"},{"key":"66367_CR95","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3390\/vaccines12040353","volume":"12","author":"G Papazisis","year":"2024","unstructured":"Papazisis, G. et al. Respiratory syncytial virus vaccines: analysis of pre-marketing clinical trials for immunogenicity in the population over 50 years of age. Vaccines 12, 353 (2024).","journal-title":"Vaccines"},{"key":"66367_CR96","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","volume":"7","author":"EY Fang","year":"2022","unstructured":"Fang, E. Y. et al. Advances in COVID-19 mRNA vaccine development. Sig. Transduct. Target. Ther. 7, 94 (2022).","journal-title":"Sig. Transduct. Target. Ther."},{"key":"66367_CR97","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40265-021-01480-7","volume":"81","author":"YN Lamb","year":"2021","unstructured":"Lamb, Y. N. BNT162b2 mRNA COVID-19 vaccine: First approval. Drugs 81, 495\u2013501 (2021).","journal-title":"Drugs"},{"key":"66367_CR98","doi-asserted-by":"publisher","first-page":"793","DOI":"10.15585\/mmwr.mm7229a4","volume":"72","author":"M Melgar","year":"2023","unstructured":"Melgar, M. et al. Use of respiratory syncytial virus vaccines in older adults: recommendations of the advisory committee on immunization practices - United States, 2023. Morb. Mortal. Wkly. Rep. 72, 793\u2013801 (2023).","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"66367_CR99","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1016\/j.celrep.2020.03.025","volume":"30","author":"L Rutten","year":"2020","unstructured":"Rutten, L. et al. Structure-based design of prefusion-stabilized filovirus glycoprotein trimers. Cell Rep. 30, 4540\u20134550.e3 (2020).","journal-title":"Cell Rep."},{"key":"66367_CR100","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22867-w","volume":"12","author":"L He","year":"2021","unstructured":"He, L. et al. Single-component multilayered self-assembling nanoparticles presenting rationally designed glycoprotein trimers as Ebola virus vaccines. Nat. Commun. 12, 2633 (2021).","journal-title":"Nat. Commun."},{"key":"66367_CR101","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1080\/21645515.2019.1651140","volume":"15","author":"JJ Suschak","year":"2019","unstructured":"Suschak, J. J. & Schmaljohn, C. S. Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates. Hum. Vaccin. Immunother. 15, 2359\u20132377 (2019).","journal-title":"Hum. Vaccin. Immunother."},{"key":"66367_CR102","doi-asserted-by":"publisher","first-page":"9596","DOI":"10.1128\/JVI.00784-09","volume":"83","author":"O Reynard","year":"2009","unstructured":"Reynard, O. et al. Ebolavirus glycoprotein GP masks both its own epitopes and the presence of cellular surface proteins. J. Virol. 83, 9596\u20139601 (2009).","journal-title":"J. Virol."},{"key":"66367_CR103","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1001098","volume":"6","author":"JR Francica","year":"2010","unstructured":"Francica, J. R. et al. Steric shielding of surface epitopes and impaired immune recognition induced by the Ebola virus glycoprotein. PLoS Pathog. 6, e1001098 (2010).","journal-title":"PLoS Pathog."},{"key":"66367_CR104","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","volume":"20","author":"N Chaudhary","year":"2021","unstructured":"Chaudhary, N., Weissman, D. & Whitehead, K. A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug Discov. 20, 817\u2013838 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"66367_CR105","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"66367_CR106","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00330-7","volume":"6","author":"B Nguyen","year":"2021","unstructured":"Nguyen, B. & Tolia, N. H. Protein-based antigen presentation platforms for nanoparticle vaccines. NPJ Vaccines 6, 70 (2021).","journal-title":"NPJ Vaccines"},{"key":"66367_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coi.2020.01.007","volume":"65","author":"DJ Irvine","year":"2020","unstructured":"Irvine, D. J. & Read, B. J. Shaping humoral immunity to vaccines through antigen-displaying nanoparticles. Curr. Opin. Immunol. 65, 1\u20136 (2020).","journal-title":"Curr. Opin. Immunol."},{"key":"66367_CR108","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.cell.2019.02.008","volume":"176","author":"R Rappuoli","year":"2019","unstructured":"Rappuoli, R. & Serruto, D. Self-assembling nanoparticles usher in a new era of vaccine design. Cell 176, 1245\u20131247 (2019).","journal-title":"Cell"},{"key":"66367_CR109","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/COH.0000000000000549","volume":"14","author":"PJM Brouwer","year":"2019","unstructured":"Brouwer, P. J. M. & Sanders, R. W. Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms. Curr. Opin. HIV AIDS 14, 302\u2013308 (2019).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"66367_CR110","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3390\/vaccines7030076","volume":"7","author":"M Brinkkemper","year":"2019","unstructured":"Brinkkemper, M. & Sliepen, K. Nanoparticle vaccines for inducing HIV-1 neutralizing antibodies. Vaccines 7, 76 (2019).","journal-title":"Vaccines"},{"key":"66367_CR111","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/COH.0000000000000366","volume":"12","author":"B Asbach","year":"2017","unstructured":"Asbach, B. & Wagner, R. Particle-based delivery of the HIV envelope protein. Curr. Opin. HIV AIDS 12, 265\u2013271 (2017).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"66367_CR112","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abm0899","volume":"14","author":"HY Huang","year":"2022","unstructured":"Huang, H. Y. et al. Vaccination with SARS-CoV-2 spike protein lacking glycan shields elicits enhanced protective responses in animal models. Sci. Transl. Med. 14, eabm0899 (2022).","journal-title":"Sci. Transl. Med."},{"key":"66367_CR113","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37742-z","volume":"14","author":"Y-N Zhang","year":"2023","unstructured":"Zhang, Y.-N. et al. Single-component multilayered self-assembling protein nanoparticles presenting glycan-trimmed uncleaved prefusion optimized envelope trimers as HIV-1 vaccine candidates. Nat. Commun. 14, 1985 (2023).","journal-title":"Nat. Commun."},{"key":"66367_CR114","doi-asserted-by":"publisher","first-page":"18137","DOI":"10.1073\/pnas.0909696106","volume":"106","author":"CC Wang","year":"2009","unstructured":"Wang, C. C. et al. Glycans on influenza hemagglutinin affect receptor binding and immune response. Proc. Natl Acad. Sci. USA 106, 18137\u201318142 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"66367_CR115","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.virol.2018.10.005","volume":"526","author":"SC Wang","year":"2019","unstructured":"Wang, S. C., Liao, H. Y., Zhang, J. Y., Cheng, T. J. R. & Wong, C. H. Development of a universal influenza vaccine using hemagglutinin stem protein produced from Pichia pastoris. Virol 526, 125\u2013137 (2019).","journal-title":"Virol"},{"key":"66367_CR116","doi-asserted-by":"publisher","first-page":"e01674","DOI":"10.1128\/mBio.01674-18","volume":"9","author":"BR West","year":"2018","unstructured":"West, B. R. et al. Structural basis of pan-ebolavirus neutralization by a human antibody against a conserved, yet cryptic epitope. mBio 9, e01674\u201318 (2018).","journal-title":"mBio"},{"key":"66367_CR117","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1016\/j.celrep.2018.08.009","volume":"24","author":"CD Murin","year":"2018","unstructured":"Murin, C. D. et al. Structural basis of pan-ebolavirus neutralization by an antibody targeting the glycoprotein fusion loop. Cell Rep. 24, 2723\u20132732 (2018).","journal-title":"Cell Rep."},{"key":"66367_CR118","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06113-4","volume":"9","author":"BM Janus","year":"2018","unstructured":"Janus, B. M. et al. Structural basis for broad neutralization of ebolaviruses by an antibody targeting the glycoprotein fusion loop. Nat. Commun. 9, 3934 (2018).","journal-title":"Nat. Commun."},{"key":"66367_CR119","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41594-019-0191-4","volume":"26","author":"BR West","year":"2019","unstructured":"West, B. R. et al. Structural basis of broad ebolavirus neutralization by a human survivor antibody. Nat. Struct. Mol. Biol. 26, 204\u2013212 (2019).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"66367_CR120","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1126\/science.1245627","volume":"342","author":"D Lyumkis","year":"2013","unstructured":"Lyumkis, D. et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 342, 1484\u20131490 (2013).","journal-title":"Science"},{"key":"66367_CR121","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1126\/science.abe1502","volume":"370","author":"S Bangaru","year":"2020","unstructured":"Bangaru, S. et al. Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. Science 370, 1089\u20131094 (2020).","journal-title":"Science"},{"key":"66367_CR122","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000139","volume":"17","author":"HL Turner","year":"2019","unstructured":"Turner, H. L. et al. Potent anti-influenza H7 human monoclonal antibody induces separation of hemagglutinin receptor-binding head domains. PLoS Biol. 17, e3000139 (2019).","journal-title":"PLoS Biol."},{"key":"66367_CR123","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3390\/v4040447","volume":"4","author":"S Bale","year":"2012","unstructured":"Bale, S. et al. Structural basis for differential neutralization of ebolaviruses. Viruses 4, 447\u2013470 (2012).","journal-title":"Viruses"},{"key":"66367_CR124","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290\u2013296 (2017).","journal-title":"Nat. Methods"},{"key":"66367_CR125","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1038\/nmeth.3541","volume":"12","author":"BA Barad","year":"2015","unstructured":"Barad, B. A. et al. EMRinger: side chain directed model and map validation for 3D cryo-electron microscopy. Nat. Methods 12, 943\u2013946 (2015).","journal-title":"Nat. Methods"},{"key":"66367_CR126","doi-asserted-by":"publisher","first-page":"5593","DOI":"10.1016\/j.cell.2021.09.035","volume":"184","author":"P Gilchuk","year":"2021","unstructured":"Gilchuk, P. et al. Pan-ebolavirus protective therapy by two multifunctional human antibodies. Cell 184, 5593\u20135607.e18 (2021).","journal-title":"Cell"},{"key":"66367_CR127","doi-asserted-by":"publisher","first-page":"23545","DOI":"10.1021\/acsnano.3c06526","volume":"17","author":"K Braz Gomes","year":"2023","unstructured":"Braz Gomes, K. et al. Single-component multilayered self-assembling protein nanoparticles displaying extracellular domains of matrix protein 2 as a pan-influenza A vaccine. ACS Nano 17, 23545\u201323567 (2023).","journal-title":"ACS Nano"},{"key":"66367_CR128","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abf1591","volume":"7","author":"L He","year":"2021","unstructured":"He, L. et al. Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates. Sci. Adv. 7, eabf1591 (2021).","journal-title":"Sci. Adv."},{"key":"66367_CR129","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abj3107","volume":"7","author":"Y-N Zhang","year":"2021","unstructured":"Zhang, Y.-N. et al. Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants. Sci. Adv. 7, eabj3107 (2021).","journal-title":"Sci. Adv."},{"key":"66367_CR130","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat4615","volume":"10","author":"R Rappuoli","year":"2018","unstructured":"Rappuoli, R. Glycoconjugate vaccines: principles and mechanisms. Sci. Transl. Med. 10, eaat4615 (2018).","journal-title":"Sci. Transl. Med."},{"key":"66367_CR131","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/ni.1946","volume":"11","author":"JG Cyster","year":"2010","unstructured":"Cyster, J. G. B cell follicles and antigen encounters of the third kind. Nat. Immunol. 11, 989\u2013996 (2010).","journal-title":"Nat. Immunol."},{"key":"66367_CR132","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nri3689","volume":"14","author":"BA Heesters","year":"2014","unstructured":"Heesters, B. A., Myers, R. C. & Carroll, M. C. Follicular dendritic cells: dynamic antigen libraries. Nat. Rev. Immunol. 14, 495\u2013504 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"66367_CR133","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1016\/j.immuni.2024.06.009","volume":"57","author":"JG Cyster","year":"2024","unstructured":"Cyster, J. G. & Wilson, P. C. Antibody modulation of B cell responses-Incorporating positive and negative feedback. Immunity 57, 1466\u20131481 (2024).","journal-title":"Immunity"},{"key":"66367_CR134","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1126\/science.aad6117","volume":"351","author":"J Misasi","year":"2016","unstructured":"Misasi, J. et al. Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science 351, 1343\u20131346 (2016).","journal-title":"Science"},{"key":"66367_CR135","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1038\/s41590-023-01559-1","volume":"24","author":"A Mart\u00ednez-Ria\u00f1o","year":"2023","unstructured":"Mart\u00ednez-Ria\u00f1o, A. et al. Long-term retention of antigens in germinal centers is controlled by the spatial organization of the follicular dendritic cell network. Nat. Immunol. 24, 1281\u20131294 (2023).","journal-title":"Nat. Immunol."},{"key":"66367_CR136","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1146\/annurev-immunol-020711-075032","volume":"30","author":"GD Victora","year":"2012","unstructured":"Victora, G. D. & Nussenzweig, M. C. Germinal centers. Annu. Rev. Immunol. 30, 429\u2013457 (2012).","journal-title":"Annu. Rev. Immunol."},{"key":"66367_CR137","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.smim.2007.12.001","volume":"20","author":"CD Allen","year":"2008","unstructured":"Allen, C. D. & Cyster, J. G. Follicular dendritic cell networks of primary follicles and germinal centers: phenotype and function. Semin. Immunol. 20, 14\u201325 (2008).","journal-title":"Semin. Immunol."},{"key":"66367_CR138","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.it.2016.10.003","volume":"37","author":"BA Heesters","year":"2016","unstructured":"Heesters, B. A., van der Poel, C. E., Das, A. & Carroll, M. C. Antigen presentation to B cells. Trends Immunol. 37, 844\u2013854 (2016).","journal-title":"Trends Immunol."},{"key":"66367_CR139","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.it.2010.03.002","volume":"31","author":"MEM El Shikh","year":"2010","unstructured":"El Shikh, M. E. M., El Sayed, R. M., Sukumar, S., Szakal, A. K. & Tew, J. G. Activation of B cells by antigens on follicular dendritic cells. Trends Immunol. 31, 205\u2013211 (2010).","journal-title":"Trends Immunol."},{"key":"66367_CR140","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41578-021-00372-2","volume":"7","author":"GA Roth","year":"2022","unstructured":"Roth, G. A. et al. Designing spatial and temporal control of vaccine responses. Nat. Rev. Mater. 7, 174\u2013195 (2022).","journal-title":"Nat. Rev. Mater."},{"key":"66367_CR141","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s44222-022-00016-2","volume":"1","author":"P Yousefpour","year":"2023","unstructured":"Yousefpour, P., Ni, K. & Irvine, D. J. Targeted modulation of immune cells and tissues using engineered biomaterials. Nat. Rev. Bioeng. 1, 107\u2013124 (2023).","journal-title":"Nat. Rev. Bioeng."},{"key":"66367_CR142","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.immuni.2007.06.007","volume":"27","author":"YR Carrasco","year":"2007","unstructured":"Carrasco, Y. R. & Batista, F. D. B cells acquire particulate antigen in a macrophage-rich area at the boundary between the follicle and the subcapsular sinus of the lymph node. Immunity 27, 160\u2013171 (2007).","journal-title":"Immunity"},{"key":"66367_CR143","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature06287","volume":"450","author":"T Junt","year":"2007","unstructured":"Junt, T. et al. Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells. Nature 450, 110\u2013114 (2007).","journal-title":"Nature"},{"key":"66367_CR144","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/ni1494","volume":"8","author":"TG Phan","year":"2007","unstructured":"Phan, T. G., Grigorova, I., Okada, T. & Cyster, J. G. Subcapsular encounter and complement-dependent transport of immune complexes by lymph node B cells. Nat. Immunol. 8, 992\u20131000 (2007).","journal-title":"Nat. Immunol."},{"key":"66367_CR145","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/ni.1745","volume":"10","author":"TG Phan","year":"2009","unstructured":"Phan, T. G., Green, J. A., Gray, E. E., Xu, Y. & Cyster, J. G. Immune complex relay by subcapsular sinus macrophages and noncognate B cells drives antibody affinity maturation. Nat. Immunol. 10, 786\u2013793 (2009).","journal-title":"Nat. Immunol."},{"key":"66367_CR146","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/ni.1856","volume":"11","author":"SF Gonzalez","year":"2010","unstructured":"Gonzalez, S. F. et al. Capture of influenza by medullary dendritic cells via SIGN-R1 is essential for humoral immunity in draining lymph nodes. Nat. Immunol. 11, 427\u2013434 (2010).","journal-title":"Nat. Immunol."},{"key":"66367_CR147","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.immuni.2007.07.009","volume":"27","author":"CD Allen","year":"2007","unstructured":"Allen, C. D., Okada, T. & Cyster, J. G. Germinal-center organization and cellular dynamics. Immunity 27, 190\u2013202 (2007).","journal-title":"Immunity"},{"key":"66367_CR148","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.cell.2019.03.016","volume":"177","author":"JG Cyster","year":"2019","unstructured":"Cyster, J. G. & Allen, C. D. C. B cell responses: cell interaction dynamics and decisions. Cell 177, 524\u2013540 (2019).","journal-title":"Cell"},{"key":"66367_CR149","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/nri2454","volume":"9","author":"FD Batista","year":"2009","unstructured":"Batista, F. D. & Harwood, N. E. The who, how and where of antigen presentation to B cells. Nat. Rev. Immunol. 9, 15\u201327 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"66367_CR150","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1126\/science.1241680","volume":"341","author":"Z Shulman","year":"2013","unstructured":"Shulman, Z. et al. T follicular helper cell dynamics in germinal centers. Science 341, 673\u2013677 (2013).","journal-title":"Science"},{"key":"66367_CR151","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.immuni.2014.10.004","volume":"41","author":"S Crotty","year":"2014","unstructured":"Crotty, S. T follicular helper cell differentiation, function, and roles in disease. Immunity 41, 529\u2013542 (2014).","journal-title":"Immunity"},{"key":"66367_CR152","doi-asserted-by":"publisher","first-page":"942897","DOI":"10.3389\/fimmu.2022.942897","volume":"13","author":"AE Powell","year":"2022","unstructured":"Powell, A. E. et al. Multimerization of Ebola GP\u0394mucin on protein nanoparticle vaccines has minimal effect on elicitation of neutralizing antibodies. Front. Immunol. 13, 942897 (2022).","journal-title":"Front. Immunol."},{"key":"66367_CR153","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz6225","volume":"6","author":"L He","year":"2020","unstructured":"He, L. et al. Proof of concept for rational design of hepatitis C virus E2 core nanoparticle vaccines. Sci. Adv. 6, eaaz6225 (2020).","journal-title":"Sci. Adv."},{"key":"66367_CR154","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54287-x","volume":"15","author":"YZ Lee","year":"2024","unstructured":"Lee, Y.-Z. et al. Rational design of uncleaved prefusion-closed trimer vaccines for human respiratory syncytial virus and metapneumovirus. Nat. Commun. 15, 9939 (2024).","journal-title":"Nat. Commun."},{"key":"66367_CR155","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41581-023-00787-w","volume":"20","author":"SE Dunn","year":"2024","unstructured":"Dunn, S. E., Perry, W. A. & Klein, S. L. Mechanisms and consequences of sex differences in immune responses. Nat. Rev. Nephrol. 20, 37\u201355 (2024).","journal-title":"Nat. Rev. Nephrol."},{"key":"66367_CR156","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nri.2016.90","volume":"16","author":"SL Klein","year":"2016","unstructured":"Klein, S. L. & Flanagan, K. L. Sex differences in immune responses. Nat. Rev. Immunol. 16, 626\u2013638 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"66367_CR157","doi-asserted-by":"publisher","first-page":"e1010805","DOI":"10.1371\/journal.ppat.1010805","volume":"18","author":"RW Cross","year":"2022","unstructured":"Cross, R. W. et al. An introduction to the Marburg virus vaccine consortium, MARVAC. PLoS Pathog. 18, e1010805 (2022).","journal-title":"PLoS Pathog."},{"key":"66367_CR158","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.3390\/vaccines9091045","volume":"9","author":"DN Wolfe","year":"2021","unstructured":"Wolfe, D. N. et al. Selection of filovirus isolates for vaccine development programs. Vaccines 9, 1045 (2021).","journal-title":"Vaccines"},{"key":"66367_CR159","doi-asserted-by":"publisher","first-page":"975","DOI":"10.3390\/vaccines12090975","volume":"12","author":"Y-N Zhang","year":"2024","unstructured":"Zhang, Y.-N. et al. A single-component multilayered self-assembling protein nanoparticle vaccine based on extracellular domains of matrix protein 2 against both influenza A and B. Vaccines 12, 975 (2024).","journal-title":"Vaccines"},{"key":"66367_CR160","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12041","volume":"7","author":"L He","year":"2016","unstructured":"He, L. et al. Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles. Nat. Commun. 7, 12041 (2016).","journal-title":"Nat. Commun."},{"key":"66367_CR161","doi-asserted-by":"publisher","first-page":"aau6769","DOI":"10.1126\/sciadv.aau6769","volume":"4","author":"L He","year":"2018","unstructured":"He, L. et al. HIV-1 vaccine design through minimizing envelope metastability. Sci. Adv. 4, aau6769 (2018).","journal-title":"Sci. Adv."},{"key":"66367_CR162","doi-asserted-by":"publisher","first-page":"113552","DOI":"10.1016\/j.celrep.2023.113552","volume":"42","author":"D Ellis","year":"2023","unstructured":"Ellis, D. et al. Antigen spacing on protein nanoparticles influences antibody responses to vaccination. Cell Rep. 42, 113552 (2023).","journal-title":"Cell Rep."},{"key":"66367_CR163","doi-asserted-by":"publisher","first-page":"1204834","DOI":"10.3389\/fimmu.2023.1204834","volume":"14","author":"M Gonzalez-Hernandez","year":"2023","unstructured":"Gonzalez-Hernandez, M. et al. Preclinical immunogenicity and protective efficacy of a SARS-CoV-2 RBD-based vaccine produced with the thermophilic filamentous fungal expression system Thermothelomyces heterothallica C1. Front. Immunol. 14, 1204834 (2023).","journal-title":"Front. Immunol."},{"key":"66367_CR164","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.vaccine.2022.01.007","volume":"40","author":"L Lazo","year":"2022","unstructured":"Lazo, L. et al. A recombinant SARS-CoV-2 receptor-binding domain expressed in an engineered fungal strain of Thermothelomyces heterothallica induces a functional immune response in mice. Vaccine 40, 1162\u20131169 (2022).","journal-title":"Vaccine"},{"key":"66367_CR165","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78425-9","volume":"10","author":"J Korn","year":"2020","unstructured":"Korn, J. et al. Baculovirus-free insect cell expression system for high yield antibody and antigen production. Sci. Rep. 10, 21393 (2020).","journal-title":"Sci. Rep."},{"key":"66367_CR166","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1107\/S1744309110038212","volume":"66","author":"M-A Elsliger","year":"2010","unstructured":"Elsliger, M.-A. et al. The JCSG high-throughput structural biology pipeline. Acta Crystallogr. Sect. F. Struct. Biol. Cryst. Commun. 66, 1137\u20131142 (2010).","journal-title":"Acta Crystallogr. Sect. F. Struct. Biol. Cryst. Commun."},{"key":"66367_CR167","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0076-6879(97)76066-X","volume":"276","author":"Z Otwinowski","year":"1997","unstructured":"Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307\u2013326 (1997).","journal-title":"Methods Enzymol."},{"key":"66367_CR168","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D. Biol. Crystallogr. 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"66367_CR169","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1107\/S2059798319011471","volume":"75","author":"D Liebschner","year":"2019","unstructured":"Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr. D: Struct. Biol. 75, 861\u2013877 (2019).","journal-title":"Acta Crystallogr. D: Struct. Biol."},{"key":"66367_CR170","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1038\/nsb1203-980","volume":"10","author":"H Berman","year":"2003","unstructured":"Berman, H., Henrick, K. & Nakamura, H. Announcing the worldwide Protein Data Bank. Nat. Struct. Biol. 10, 980 (2003).","journal-title":"Nat. Struct. Biol."},{"key":"66367_CR171","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1107\/S0907444903008126","volume":"59","author":"E Potterton","year":"2003","unstructured":"Potterton, E., Briggs, P., Turkenburg, M. & Dodson, E. A graphical user interface to the CCP4 program suite. Acta Crystallogr. D. Biol. Crystallogr. 59, 1131\u20131137 (2003).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"66367_CR172","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jsb.2006.05.009","volume":"157","author":"G Tang","year":"2007","unstructured":"Tang, G. et al. EMAN2: An extensible image processing suite for electron microscopy. J. Struct. Biol. 157, 38\u201346 (2007).","journal-title":"J. Struct. Biol."},{"key":"66367_CR173","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen, E. F. et al. UCSF chimera - A visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605\u20131612 (2004).","journal-title":"J. Comput. Chem."},{"key":"66367_CR174","doi-asserted-by":"publisher","DOI":"10.1002\/pro.4792","volume":"32","author":"EC Meng","year":"2023","unstructured":"Meng, E. C. et al. UCSF ChimeraX: Tools for structure building and analysis. Protein Sci. 32, e4792 (2023).","journal-title":"Protein Sci."},{"key":"66367_CR175","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pro.3943","volume":"30","author":"EF Pettersen","year":"2021","unstructured":"Pettersen, E. F. et al. UCSF ChimeraX: Structure visualization for researchers, educators, and developers. Protein Sci. 30, 70\u201382 (2021).","journal-title":"Protein Sci."},{"key":"66367_CR176","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/pro.3235","volume":"27","author":"TD Goddard","year":"2018","unstructured":"Goddard, T. D. et al. UCSF ChimeraX: Meeting modern challenges in visualization and analysis. Protein Sci. 27, 14\u201325 (2018).","journal-title":"Protein Sci."},{"key":"66367_CR177","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/prot.21085","volume":"65","author":"J Zhu","year":"2006","unstructured":"Zhu, J., Xie, L. & Honig, B. Structural refinement of protein segments containing secondary structure elements: Local sampling, knowledge-based potentials, and clustering. Proteins: Struct. Funct. Bioinf. 65, 463\u2013479 (2006).","journal-title":"Proteins: Struct. Funct. Bioinf."},{"key":"66367_CR178","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/(SICI)1097-0134(199710)29:2<240::AID-PROT11>3.0.CO;2-O","volume":"29","author":"BL deGroot","year":"1997","unstructured":"deGroot, B. L. et al. Prediction of protein conformational freedom from distance constraints. Proteins: Struct. Funct. Genet. 29, 240\u2013251 (1997).","journal-title":"Proteins: Struct. Funct. Genet."},{"key":"66367_CR179","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1006\/jmbi.1997.1479","volume":"275","author":"R Samudrala","year":"1998","unstructured":"Samudrala, R. & Moult, J. An all-atom distance-dependent conditional probability discriminatory function for protein structure prediction. J. Mol. Biol. 275, 895\u2013916 (1998).","journal-title":"J. Mol. Biol."},{"key":"66367_CR180","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671\u2013675 (2012).","journal-title":"Nat. Methods"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66367-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66367-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66367-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T14:03:50Z","timestamp":1766498630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66367-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":180,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["66367"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-66367-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"2 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Jiang Zhu is the Co-Founder and a Scientific Advisory Board member of Uvax Bio, LLC, and holds associated financial interests. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11368"}}